|Bid||1.2000 x 1300|
|Ask||1.3200 x 1000|
|Day's Range||1.2100 - 1.3100|
|52 Week Range||0.6470 - 3.6400|
|Beta (5Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.29|
Selecta Biosciences ( NASDAQ:SELB ) Third Quarter 2022 Results Key Financial Results Revenue: US$20.7m (down 15% from...
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th A
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?